Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Update

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the target of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 112,008 shares, an increase of 827.2% from the April 30th total of 12,080 shares. Based on an average daily volume of 927 shares, the days-to-cover ratio is currently 120.8 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating on shares of Hansa Biopharma AB (publ) in a research report on Thursday, February 12th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.

Hansa Biopharma AB (publ) Price Performance

HNSBF stock opened at $2.90 on Thursday. Hansa Biopharma AB has a one year low of $2.90 and a one year high of $2.90. The company’s 50 day moving average price is $2.90 and its two-hundred day moving average price is $2.91.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.